Date: 2015-06-03
Type of information: Presentation of results at a congress
phase: 1
Announcement: presentation of results at the European League Against Rheumatism (EULAR) Annual Congress in Rome
Company: Celgene (USA - NJ)
Product: CC-220
Action mechanism:
Disease: systemic lupus erythematosus (SLE)
Therapeutic area: Autoimmune diseases – Inflammatory diseases
Country: USA
Trial
details: The purpose of this study is to determine whether CC-220 is effective for the treatment of skin, joint and serological manifestations of systemic lupus erythematosus. (NCT02185040)
Latest
news: * On June 3, 2015, Celgene announced that data evaluating CC-220 will be presented at the European League Against Rheumatism (EULAR) Annual Congress in Rome. Data will be presented on the effect of CC-220 on blood cell levels of Ikaros and Aiolos - transcription factors that, when mutated, are associated with an increased risk of systemic lupus erythematosus. The presentation will include phase I data on the impact of CC-220 on the immune response in healthy volunteers. A phase 2 trial is currently ongoing.
